# Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

> **NCT00840931** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 22 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** lenalidomide
- **BIOLOGICAL:** bystander vaccine

## Key facts

- **NCT ID:** NCT00840931
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-02
- **Primary completion:** 2014-02-17
- **Final completion:** 2019-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2019-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00840931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00840931, "Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00840931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*